Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer
Interventions: DRUG: Eribulin Mesylate|DRUG: Anlotinib hydrochloride
Sponsor: The First Affiliated Hospital with Nanjing Medical University